Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true figure may be higher, as the symptoms develop slowly and thus may go ...

At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...

"Oczyesa has the potential to advance the standard of care for patients living with acromegaly by enhancing ... of mean IGF-1 values and reduction of symptoms were confirmed over 52 weeks in ...

for maintenance therapy in adults with acromegaly who have previously responded to somatostatin analogues. Fredrik Tiberg, President & CEO of Camurus, noted that Oczyesa's monthly autoinjector pen ...

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

Acromegaly was still suspected ... removal of the pituitary microadenoma resulted in significant improvement in symptoms. The case report underscored “the value of considering genetic and ...

Furthermore, the study showed improvements in symptoms, quality of life ... on quality of life and mortality of patients with acromegaly.5,6 The prevalence of acromegaly is estimated to about ...

Furthermore, the study showed improvements in symptoms, quality of life ... of three chronic and severe disease indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET ...